| *Sponsored
(Nasdaq: ALBT) Reaches New Milestone Towards Accelerating Commercial Expansion (Breaking News)
July 28th Greetings, Friend!
Avalon GloboCare Corp. (Nasdaq: ALBT) is making moves first thing Monday.
Going green quickly, ALBT may be piggybacking off of today's huge announcement. Check it out:
Avalon GloboCare Enters into Distribution Agreement with Saga Health for KetoAir Targeting First Responders
FREEHOLD, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced that its subsidiary, Q&A Distribution, LLC, has entered into a wholesale distribution agreement with Saga Health Corporation (“Saga Health”) for its use of the KetoAir™ breathalyzer device in its first responder-targeted Holistic Health Reset Program.
...
“We believe that this agreement with Saga Health marks a milestone in accelerating the commercial expansion of KetoAir™,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “KetoAir™ is a unique, science-driven tool that supports the growing demand for personalized, real-time monitoring of BrAce, and is intended for those pursuing ketogenic lifestyles. We’re pleased to collaborate with our partner Saga Health to further our goal of accelerating the commercial expansion of the KetoAir™.”
...
Read the full article here.
On top of the awesome news, it's key to note that ALBT is a low float idea with roughly 1.45Mn shares available.
That means volatility potential could be heightened on a daily basis (and especially after today's positive news).
Take a moment to review my initial report on (Nasdaq: ALBT) and consider this profile for your radar. -----
See this past Friday's breakout idea?
Swinging from a low of $1.10, it rocketed to a two-week high of $1.45.
That move resulted in a surge of approx. 31% intraday!
Not shabby, but here's this...
A recently proposed merger could start propelling a biotech innovator into new frontiers of AI-driven business automation, combining cutting-edge medical science with advanced technology solutions.
This union could enhance operational efficiencies while accelerating growth in both heal.thcare and AI sectors.
Positioned at the intersection of these rapidly evolving industries, this collaboration signals transformative potential at the ground floor.
And with a low float of fewer than 2Mn shares, game-changing news in the recent term, and this proposed merger stirring buzz, there should be little confusion as to why this Nasdaq breakout idea is on my radar:
Avalon GloboCare Corp. (Nasdaq: ALBT)
Avalon GloboCare Corp. is a developer of precision diagnostic consumer products and the advancement of intellectual property in cellular therapy.
Avalon is currently marketing the KetoAir™ breathalyzer device, which is owned and manufactured by Qi Diagnostics Limited, and plans to develop additional diagnostic uses of the breathalyzer technology.
Delivering Precision Diagnostics and Laboratory Services
Avalon achieves and fosters seamless integration of unique verticals to bridge and accelerate innovative research, bio-process development, clinical programs and product commercialization.
Research and Development
Avalon is focused on bringing forward intellectual property through joint patent filings with the Massachusetts Institute of Technology (MIT), led by Professor Shuguang Zhang as Principal Investigator.
- Using the unique QTY code protein design platform, six water-soluble variant cytokine receptors have been successfully designed and tested to show binding affinity to the respective cytokines. The company is currently focused on bringing forward the intellectual property associated with this program through joint patent submissions.
KetoAir™ Breathalyzer
Avalon is exploring the commercialization and development of a versatile breathalyzer system.
The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath.
The acetone level is in concentration units (ppm, part-per-million) such that the user will know his/her real-time ketosis status: inadequate ketosis (0-3.99 ppm), mild ketosis (4-9.99 ppm), optimal ketosis (10-40 ppm), or alarming level (> 40 ppm).
The breathalyzer is registered with the United States FDA as a Class I medical device (US FDA registration # 3026284320). | 
0 Response to "(Nasdaq: ALBT) Reaches New Milestone Towards Accelerating Commercial Expansion (Breaking News)"
Post a Comment